A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer.
Clinical Cancer Research.
Times cited: 65
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 51
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
New England Journal of Medicine.
Times cited: 471